Quantum dot-based assays to offer new ways to understand cell biology

“We are excited by the prospect of EviTags and are pleased to be working with this new form of quantum dot nanobiotechnology. We believe that EviTags offer many advantages to understanding
cells that will be very important for our research and biotech industry customers,” said Sheridan G.
Snyder, Chairman and CEO of Upstate. “Evident Technologies' new quantum dot technology, combined with our cell signaling capabilities may lead to many new ways to conduct cell research.”

“We are looking forward to working with Upstate, the leader in many innovative and advanced cell
signaling products, using our EviTags. Conjugating proteins to quantum dots offer distinct advantages over traditional organic fluorophores, including greatly improved photostability, color multiplexing, and single-source excitation,” said Clinton Ballinger, Ph.D., CEO of Evident Technologies, “With these attributes, researchers can perform more tests, see more detail within cells and the freedom to perform long-term imaging.”

Quantum dot conjugates are the next stage in the evolution of biotechnology research tools and offer improved photostability, single source optical excitation, and a multiplicity of tunable narrow-band emission colors that span the visible and infrared spectrum. With these attributes, researchers can perform more tests, see more details in cells and have freedom to perform long-term imaging.

The original press release can be found here.